Goldman Sachs
ORGO icon

Goldman Sachs’s Organogenesis Holdings ORGO Stock Holding History

Goldman Sachs’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
520,350
+102,106
+24% +$354K ﹤0.01% 4938
2025
Q4 		$2.17M Buy
418,244
+188,958
+82% +$916K ﹤0.01% 4515
2025
Q3 		$968K Buy
229,286
+29,601
+15% +$138K ﹤0.01% 5049
2025
Q2 		$731K Sell
199,685
-222,345
-53% -$829K ﹤0.01% 4920
2025
Q1 		$1.82M Sell
422,030
-234,126
-36% -$945K ﹤0.01% 4233
2024
Q4 		$2.1M Buy
656,156
+383,525
+141% +$1.29M ﹤0.01% 4235
2024
Q3 		$780K Buy
272,631
+24,681
+10% +$69.2K ﹤0.01% 4808
2024
Q2 		$694K Buy
247,950
+61,083
+33% +$164K ﹤0.01% 4645
2024
Q1 		$531K Sell
186,867
-17,131
-8% -$58.2K ﹤0.01% 4723
2023
Q4 		$834K Sell
203,998
-67,955
-25% -$190K ﹤0.01% 4483
2023
Q3 		$865K Buy
271,953
+55,957
+26% +$178K ﹤0.01% 4370
2023
Q2 		$717K Sell
215,996
-398,588
-65% -$1.18M ﹤0.01% 4542
2023
Q1 		$1.31M Sell
614,584
-161,068
-21% -$398K ﹤0.01% 4186
2022
Q4 		$2.09M Sell
775,652
-191,444
-20% -$558K ﹤0.01% 3912
2022
Q3 		$3.13M Sell
967,096
-81,215
-8% -$367K ﹤0.01% 3565
2022
Q2 		$5.12M Buy
1,048,311
+124,825
+14% +$768K ﹤0.01% 3113
2022
Q1 		$7.04M Buy
923,486
+91,143
+11% +$705K ﹤0.01% 3026
2021
Q4 		$7.69M Buy
832,343
+80,810
+11% +$858K ﹤0.01% 3001
2021
Q3 		$10.7M Sell
751,533
-400,890
-35% -$6.23M ﹤0.01% 2658
2021
Q2 		$19.2M Buy
1,152,423
+1,057,263
+1,111% +$19.7M ﹤0.01% 2081
2021
Q1 		$1.73M Buy
95,160
+26,476
+39% +$359K ﹤0.01% 4129
2020
Q4 		$517K Buy
68,684
+39,597
+136% +$188K ﹤0.01% 4590
2020
Q3 		$112K Sell
29,087
-25,489
-47% -$101K ﹤0.01% 5064
2020
Q2 		$210K Buy
54,576
+36,520
+202% +$132K ﹤0.01% 4777
2020
Q1 		$58K Sell
18,056
-1,075
-6% -$4.6K ﹤0.01% 5026
2019
Q4 		$92K Buy
+19,131
New +$121K ﹤0.01% 5053
2019
Q2 		– Sell
-101,512
Closed -$761K – 5295
2019
Q1 		$761K Buy
+101,512
New +$2.03M ﹤0.01% 4207

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs's ORGO Position: Q1 2026 in Review

Goldman Sachs increased its Organogenesis Holdings (ORGO) stake by 24% in Q1 2026, buying an estimated $354K and bringing the position to 520,350 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #4938.

Goldman Sachs first reported a position in ORGO in Q1 2019 and has held it in 27 quarters since. The position peaked at $19.2M in Q2 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Goldman Sachs held 520,350 shares of Organogenesis Holdings worth $1.23M as of Q1 2026.
  • Goldman Sachs bought 102,106 Organogenesis Holdings shares in Q1 2026, an estimated $354K.
  • Organogenesis Holdings made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4938 holding.
  • Goldman Sachs first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 27 quarters since.
  • Goldman Sachs's Organogenesis Holdings position peaked at $19.2M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.